What to expect in the Denali Therapeutics Inc. interview process

Based on publicly available sources, Denali Therapeutics is a publicly traded biotechnology company headquartered in South San Francisco, California, with additional offices in locations like Salt Lake City and a workforce distributed across eight countries, including Switzerland, Canada, Germany, and Turkey. Founded in 2015, the company focuses on discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases—such as Alzheimer’s, Parkinson’s, and ALS—utilizing its proprietary TransportVehicle™ platform designed to cross the blood-brain barrier.

Workforce intelligence data shows that Denali employs approximately 458 to 516 people globally, reflecting moderate headcount growth over recent years. The company pairs in-house research with strategic partnerships to share development risks and advance its pipeline. Public hiring data indicates that the company actively recruits for scientific and operational roles, though active job postings experienced a 40.0% decline in 2026 compared to the previous year, shifting from 2025 levels down to 38 active postings. Leadership includes co-founders and executives with deep industry backgrounds, such as COO Alexander Schuth, who brings prior operational and neuroscience partnering experience from Genentech.